Leading Brands, Inc. (LBIX) Forms $1.63 Double Bottom; PTC Therapeutics, Inc. (PTCT) Had 4 Bullish Analysts

December 31, 2017 - By Jerrie Dane

Leading Brands, Inc. (LBIX) formed double bottom with $1.52 target or 7.00% below today’s $1.63 share price. Leading Brands, Inc. (LBIX) has $4.57M valuation. The stock decreased 6.32% or $0.11 during the last trading session, reaching $1.63. About 296,058 shares traded. Leading Brands, Inc. (NASDAQ:LBIX) has risen 3.99% since December 31, 2016 and is uptrending. It has underperformed by 12.71% the S&P500.

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. PTC Therapeutics had 34 analyst reports since July 31, 2015 according to SRatingsIntel. Bank of America downgraded the shares of PTCT in report on Thursday, October 26 to “Sell” rating. The rating was initiated by Citigroup with “Buy” on Tuesday, August 25. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Outperform” rating given on Wednesday, January 20 by Credit Suisse. RBC Capital Markets downgraded PTC Therapeutics, Inc. (NASDAQ:PTCT) on Wednesday, February 24 to “Sector Perform” rating. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Neutral” rating given on Tuesday, February 23 by JP Morgan. RBC Capital Markets maintained the shares of PTCT in report on Friday, October 16 with “Outperform” rating. RBC Capital Markets maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) rating on Wednesday, August 9. RBC Capital Markets has “Hold” rating and $1500 target. RBC Capital Markets maintained it with “Hold” rating and $15.0 target in Wednesday, October 25 report. On Thursday, November 16 the stock rating was upgraded by J.P. Morgan to “Hold”. The firm has “Sector Perform” rating given on Friday, November 11 by RBC Capital Markets. See PTC Therapeutics, Inc. (NASDAQ:PTCT) latest ratings:

16/11/2017 Broker: J.P. Morgan Rating: Hold New Target: $15.0 Upgrade
16/11/2017 Broker: JP Morgan Old Rating: Underweight New Rating: Neutral Upgrade
26/10/2017 Broker: Bank of America Rating: Sell New Target: $14.0 Downgrade
25/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $15.0 Maintain
09/10/2017 Broker: J.P. Morgan Rating: Sell Downgrade
09/10/2017 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
29/09/2017 Broker: Barclays Capital Rating: Hold New Target: $15.0
26/09/2017 Broker: J.P. Morgan Rating: Hold Maintain
26/09/2017 Broker: Credit Suisse Rating: Buy New Target: $25.0
14/09/2017 Broker: RBC Capital Markets Rating: Hold New Target: $15.0 Maintain

Investors sentiment increased to 1.71 in Q3 2017. Its up 0.79, from 0.92 in 2017Q2. It is positive, as 13 investors sold PTC Therapeutics, Inc. shares while 28 reduced holdings. 25 funds opened positions while 45 raised stakes. 32.89 million shares or 5.85% more from 31.07 million shares in 2017Q2 were reported. The Maryland-based Proshare Ltd Liability Co has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Northern Tru stated it has 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Federated Investors Incorporated Pa has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Sectoral Asset Management, a Quebec – Canada-based fund reported 170,535 shares. Wellington Management Grp Limited Liability Partnership holds 0.01% or 1.15M shares. Voya Inv Mngmt holds 18,215 shares or 0% of its portfolio. Balyasny Asset Management Llc invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Ghost Tree Capital Ltd Liability Com holds 0.42% or 100,000 shares. Sei Invs, a Pennsylvania-based fund reported 1,115 shares. Great Point Partners Ltd Liability Corporation invested 4.28% in PTC Therapeutics, Inc. (NASDAQ:PTCT). The United Kingdom-based Barclays Plc has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Great West Life Assurance Can reported 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). 11,460 were accumulated by Los Angeles Capital Mngmt And Equity Incorporated. Credit Suisse Ag invested in 0% or 57,666 shares. State Board Of Administration Of Florida Retirement System holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 21,987 shares.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company has market cap of $692.05 million. The companyÂ’s lead product is Translarna , for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It currently has negative earnings. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.

The stock decreased 0.18% or $0.03 during the last trading session, reaching $16.68. About 607,409 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since December 31, 2016 and is uptrending. It has outperformed by 87.81% the S&P500.